LEX DIAGNOSTICS LIMITED

• ⚠

  Material uncertainty over going concern

  In the opinion of the directors, each of the two matters noted above represents a material uncertainty related to events of conditions that may cast significant doubt on the company's ability to continue as a going concern.

• ◆

  4 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  —

  Not reported

• Cash

  -71.3%

  £2,508,000 → £719,000

• Net assets

  -45.5%

  -£40,585,000 → -£59,045,000

• Employees

  +31.3%

  32 → 42

• Operating profit

  +4.9%

  -£16,311,000 → -£15,510,000

• Profit before tax

  -2.6%

  -£19,056,000 → -£19,549,000

• Wages

  +34.9%

  £2,004,000 → £2,703,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“In the opinion of the directors, each of the two matters noted above represents a material uncertainty related to events of conditions that may cast significant doubt on the company's ability to continue as a going concern.”

Significant events

• “During the year LEX Diagnostics finalised the development of the first generation of its instrument and consumables to enable fast, cost-effective PCR at point of care. A major focus for the year has been the verification and validation of the VELO system, including the management of clinical and usability studies in the United States in preparation for submission, in June 2025, of the product to the FDA for clearance.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

14

last 12 months

Capital events

1

last 24 months

Officers appointed

5

last 12 months

Officers resigned

4

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.